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OBJECTIVE—Diabetic retinopathy is a sight-threatening micro-
vascular complication of diabetes with a complex multifactorial
pathogenesis. A systematic meta-analysis was undertaken to
collectively assess genetic studies and determine which previ-
ously investigated polymorphisms are associated with diabetic
retinopathy.
RESEARCH DESIGN AND METHODS—All studies investigat-
ing the association of genetic variants with the development of
diabetic retinopathy were identiﬁed in PubMed and ISI Web of
Knowledge. Crude odds ratios (ORs) and 95% CIs were calcu-
lated for single nucleotide polymorphisms and microsatellite
markers previously investigated in at least two published studies.
RESULTS—Twenty genes and 34 variants have previously been
studied in multiple cohorts. The aldose reductase (AKR1B1)
gene was found to have the largest number of polymorphisms
signiﬁcantly associated with diabetic retinopathy. The z2 micro-
satellite was found to confer risk (OR 2.33 [95% CI 1.49–3.64],
P  2  10
4) in type 1 and type 2 diabetes and z2 to confer
protection (0.58 [0.36–0.93], P  0.02) against diabetic retinop-
athy in type 2 diabetes regardless of ethnicity. The T allele of the
AKR1B1 promoter rs759853 variant is also signiﬁcantly protec-
tive against diabetic retinopathy in type 1 diabetes (0.5 [0.35–
0.71], P  1.00  10
4), regardless of ethnicity. These
associations were also found in the white population alone (P 
0.05). Polymorphisms in NOS3, VEGF, ITGA2, and ICAM1 are
also associated with diabetic retinopathy after meta-analysis.
CONCLUSIONS—Variations within the AKR1B1 gene are
highly signiﬁcantly associated with diabetic retinopathy develop-
ment irrespective of ethnicity. Identiﬁcation of genetic risk
factors in diabetic retinopathy will assist in further understand-
ing of this complex and debilitating diabetes complication.
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D
iabetic retinopathy is a sight-threatening micro-
vascular complication of diabetes. Global popu-
lation–based data indicate that it is the ﬁfth
most common cause of blindness in the world,
accounting for 4.8% of global blindness (1). Diabetic
retinopathy is a leading cause of blindness in industrial-
ized countries (1), and its signiﬁcance is likely to increase
with increasing frequency of diabetes (2). Diabetic reti-
nopathy is deﬁned by the presence of retinal microvascu-
lar lesions. Early retinal changes include microaneurysms,
hemorrhages, hard exudates, cotton wool spots, intrareti-
nal microvascular abnormalities, and venous beading.
These clinical features occur in nonproliferative diabetic
retinopathy (NPDR). Growth of abnormal new blood ves-
sels that frequently lead to preretinal and vitreous hemor-
rhage are the principal hallmarks of proliferative diabetic
retinopathy (PDR). Visual impairment in diabetic retinop-
athy occurs secondary to preretinal or vitreous hemor-
rhage and diabetic maculopathy (either macular edema or
macular ischemia) (3).
The prevalence of diabetic retinopathy is higher in type
1 diabetic patients, with sight-threatening retinopathy re-
ported to be up to 2.5 times more common than in those
with type 2 diabetes (4). Conversely, the incidence of
macular edema has been reported to be up to two times
higher among those with type 2 diabetes (5).
The pathogenesis of diabetes is believed to be multifac-
torial, with genetic risk factors playing a fundamental role.
Recent genome-wide association studies have identiﬁed
several genetic loci involved in the pathogenesis of both
type 1 diabetes and type 2 diabetes (6,7). Pathogenesis of
diabetic retinopathy is complex, also having a multifacto-
rial biochemical pathogenesis, primarily because of al-
tered glucose metabolism (8). Glycemic control (9,10) and
the duration of diabetes (11,12) have been identiﬁed
through large longitudinal prospective studies as being
major risk factors for the development of diabetic retion-
opathy. However, genetic factors are also likely to account
for the susceptibility to this blinding disease as well as the
differences in diabetic retinopathy incidence between in-
dividuals with type 1 and type 2 diabetes. It has become
evident through familial aggregation studies that suscepti-
bility to complications of diabetes such as diabetic reti-
nopathy also have a heritable component independent of
glycemic control and duration of diabetes. The Diabetes
Control and Complications Trial revealed a familial ten-
dency for severe diabetic retinopathy in type 1 and type 2
diabetes (13). These ﬁndings were also replicated in
Mexican Americans (14,15) and other familial risk studies
(16,17), independent of associated environmental risk
factors. There have been numerous studies investigating
candidate genes for diabetic retinopathy susceptibility in
subjects of various ethnicities.
The aim of this systematic meta-analysis was to analyze
all published studies that investigated the association
between genetic risk factors and the development of
diabetic retinopathy and met speciﬁed inclusion criteria.
We sought to determine which of the previously investi-
gated genetic variants are signiﬁcantly associated with
the development of diabetic retinopathy in type 1 or type
2 diabetes and to examine the strength of these
associations.
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Literature search and data collection. A systematic literature search was
performed to identify all studies published between January 1990 and August
2008 that investigated the association of genetic variants with the develop-
ment of any form of diabetic retinopathy. The PubMed database (National
Center for Biotechnology Information; NCBI), ISI Web of Knowledge (version
4.5), and the Cochrane Library were explored independently by two authors
using the following keyword strings: “genetic” AND “diabetic retinopathy” and
“gene” AND “diabetic retinopathy.” All retrieved publications were reviewed
and compared and studies written in English that contained sufﬁcient case
(subjects with diabetes and diabetic retinopathy) and control (subjects with
diabetes but without the complication of diabetic retinopathy) subjects’
genotype information, such as allele or genotype frequency, were included.
The reference list of each relevant publication was also examined to identify
additional studies appropriate for inclusion in the meta-analysis. Polymor-
phisms were included in the meta-analysis if a minimum of two studies had
assessed association with diabetic retinopathy development.
Data analysis. Data were entered into a database and statistical analyses
performed using RevMan software (version 4.2; Oxford, U.K.) and SPSS
(version 16.0; SPSS, Chicago, IL). Data extraction and data entry was
performed independently by two of the authors (S.A. and A.W.H.) and
compared. Independent review and resolution by a senior investigator (K.P.B.
and J.E.C.) was sought if disagreement between the reviewers occurred.
Ensemble (http://www.ensembl.org/index.html) and dbSNP (http://www.
ncbi.nlm.nih.gov/SNP/) were used to locate rs# identiﬁers for the genetic
variants. When an rs# identiﬁer could not be located, the most commonly used
name for that speciﬁc variant or single nucleotide polymorphism (SNP) was
selected. All rs# identiﬁers were conﬁrmed independently by a senior inves-
tigator (K.P.B.).
Analyses were performed for all cases with any form of diabetic retinop-
athy compared with all diabetic subjects without diabetic retinopathy (control
subjects). Subanalysis was subsequently undertaken for NPDR and PDR
where possible. Major and minor allele frequencies were calculated from the
available genetic data of all reported variants in the included studies and odds
ratios (ORs) and 95% CIs were calculated. The allelic association of micro-
satellite markers was also investigated, whereby the risk conferred by each
allele was compared against all other alleles as well as against speciﬁc alleles.
The Der Simonian and Laird random-effects model was used (18,19). This
model utilizes weights that incorporate both within-study and between-study
variance. Heterogeneity between studies was calculated as the inverse vari-
ance estimate. To minimize genetic heterogeneity, subanalysis was performed
for all cohorts of white origin and for datasets in which heterogeneity
remained; outlying studies were then removed in a stepwise fashion until
homogeneity was achieved (20). For the purpose of this study, white ancestry
was deﬁned as being of European descent. Studies including subjects of white
and nonwhite ancestry have had their cohorts divided and analyzed individ-
ually. Funnel plots were constructed in Revman and Egger’s test (21) applied
in Stata (version 10.1; Stata, College Station, TX) to investigate for publication
bias. A P value of 0.05 was considered statistically signiﬁcant in all analyses,
except for publication bias (Egger’s test), where a P value of 0.1 (22) was
considered as statistically signiﬁcant. No adjustments were made for multiple
testing.
RESULTS
There were 702 publications identiﬁed. Of these, 160 were
speciﬁc to genetic polymorphisms and the development of
diabetic retinopathy (Fig. 1). Twelve of these studies were
in a language other than English and were excluded, and a
ﬁnal total of 82 studies were suitable for inclusion as a
result of having presented sufﬁcient case and control
genotype information. There were 196 polymorphisms
identiﬁed, with 34 of these having adequate genotype data
for inclusion in the meta-analysis. Visual inspection of the
funnel plots revealed a symmetrical inverted V shape and
Egger’s test did not detect signiﬁcant publication bias
(P  0.1) for all polymorphisms examined by more than
ﬁve studies (supplementary Fig. 1, available in an online
appendix at http://diabetes.diabetesjournals.org/cgi/content/
full/db09-0059/DC1).
Seven polymorphisms were investigated by more than
ﬁve studies and are discussed in detail (Table 1). Details of
their study design are provided in supplementary Table 1.
Forty-eight studies were included in the analyses for the
seven polymorphisms, 20 (42%) of which included subjects
of white ancestry (Table 2). Heterogeneity was eliminated
in the subanalyses of studies with participants of white
ancestry without the requirement of removal of outlying
studies, indicating that ethnicity is a major source of
heterogeneity generally.
Data on the remaining 27 SNPs analyzed in the current
study, which have been examined by a minimum of two
and maximum of ﬁve cohorts, are presented in Table 3.
The rs2910964 SNP of the 2	1 integrin (ITGA2) gene (OR
1.65 [95% CI 1.26–2.15], P  2  10
4) and rs13306430 of
the intercellular cell adhesion molecule 1 (ICAM1) gene
(0.56 [0.39–0.81], P  1.70  10
3) were signiﬁcantly
associated with diabetic retinopathy, both being examined
in type 2 diabetes only and by two studies in each case.
ACE. The gene encoding ACE is located on chromosome
17q23. Six studies examined the insertion/deletion (INS/
DEL) polymorphism in intron 16 of the ACE gene in
patients with type 1 diabetes, and seven studies in patients
with type 2 diabetes were included in the meta-analysis.
The 287 base pair deletion was treated as the risk variant,
and there was no statistically signiﬁcant association with
this polymorphism and the development of any form of
diabetic retinopathy (Table 1).
543 contained no data pertaining to genetic association with diabetic retinopathy
702 publications identified and reviewed
160 publications specific to genetic polymorphisms and diabetic retinopathy
196 variants in 65 genes
12 studies published in a language other than English
11 studies including only case
 
or control data
55 studies with insufficient genotype information
82 publications containing sufficient case and control data included
34 variants of 20 genes included
FIG. 1. Flow chart of study selection process and included studies.
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lyzed for all diabetic retinopathy comparisons. The 287
base pair deletion was not found to be signiﬁcantly asso-
ciated with any diabetic retinopathy or its subtypes in type
1 or type 2 diabetes (Table 2).
Aldose reductase (AKR1B1). The aldo-keto reductase
family 1 member B1 (AKR1B1) gene (also known as ALR)
is located on chromosome 7q35. Associations of two
AKR1B1 SNPs with diabetic retinopathy have been re-
ported in the literature: the promoter SNP rs759853 and
the (CA)n microsatellite polymorphism located 5 of the
AKR1B1 gene. Six studies have examined the association
between the AKR1B1 (CA)n microsatellite with diabetic
retinopathy in type 1 and nine studies in type 2 diabetes
(Table 1). The three most commonly investigated AKR1B1
variants (z, z2, and z2) in the literature were included
for analysis.
There was a signiﬁcant association with the z2 allele
and the development of any diabetic retinopathy (OR 2.33
[95% CI 1.49–3.64], P  2  10
4). Subanalyses revealed a
signiﬁcant association between the z2 allele and diabetic
retinopathy in patients with type 2 diabetes (2.64 [1.39–
5.01], P  2.9  10
3), with weaker but statistically
signiﬁcant association also being found for patients with
type 1 diabetes (1.95 [1.04–3.66], P  0.04). A signiﬁcant
association was also found in the NPDR and PDR
subgroups.
No statistically signiﬁcant association was found be-
tween the z allele and the development of diabetic retinop-
athy overall (OR 1.05 [95% CI 0.81–1.35], P  0.73).
However, in the subanalysis for type of diabetic retinopa-
thy, the z allele was signiﬁcantly protective against NPDR
development in type 2 diabetes (0.65 [0.45–0.94], P 
0.02). A signiﬁcant difference between NPDR and PDR
development for the presence of z allele was found also in
type 2 diabetes (0.65 [0.45–0.94], P  0.02). Similarly, the
z2 allele was found to be signiﬁcantly protective against
the development of diabetic retinopathy (0.58 [0.36–0.93],
P  0.02).
Only four studies examining the AKR1B1 (CA)n micro-
satellite have included subjects of white ancestry (Table
2), with the majority of studies including subjects of only
Asian ancestry. In the analyses of studies of white origin,
only the z2 (OR 1.80 [95% CI 1.06–3.06], P  0.03) and
z2 (0.56 [0.32–0.97], P  0.04) polymorphisms remained
signiﬁcantly associated with diabetic retinopathy, with the
z2 allele conferring risk and z2 conferring protection
against diabetic retinopathy.
Three studies examined the association of a second
AKR1B1 polymorphism (promoter SNP rs759853) with
diabetic retinopathy in type 1 diabetes and ﬁve studies in
type 2 diabetes (Table 1). The T allele was considered the
risk variant. Interestingly, analyses revealed protection
against diabetic retinopathy with the T allele in type 1
diabetes (OR 0.49 [95% CI 0.36–0.68], P  1.00  10
4).
There was no statistically signiﬁcant association between
diabetic retinopathy and rs759853 in type 2 diabetes.
However, a borderline association between NPDR and
PDR was found (0.73 [0.54–0.99], P  0.04).
Four studies investigating the AKR1B1 rs759853 in-
cluded subjects of white ancestry. A signiﬁcant protection
of the T allele against diabetic retinopathy in type 1
diabetes (OR 0.5 [95% CI 0.35–0.71], P  1.00  10
4)
remained. Insufﬁcient studies were available for subanaly-
sis of diabetic retinopathy subtypes.
Vascular endothelial growth factor. The vascular endo-
thelial growth factor (VEGF) gene is located on chromo-
some 6p12. Six VEGF polymorphisms were included in
this meta-analysis, with the rs2010963 polymorphism be-
ing the most frequently studied. No studies examining this
polymorphism in type 1 diabetes and diabetic retinopathy
were located. Seven studies examining this polymorphism
in type 2 diabetes and diabetic retinopathy were included
in the analyses (Table 1). The G allele has been considered
as the risk variant. A signiﬁcant association between
patients with no diabetic retinopathy and those with
NPDR (OR 0.62 [95% CI 0.48–0.81], P  5.0  10
4) was
identiﬁed, yet no signiﬁcant differences were found be-
tween NPDR and PDR development. Meta-analysis re-
vealed no signiﬁcant association between the VEGF
polymorphisms: rs25648, rs1570360, rs3095039, rs35569394,
or rs699947 and any type of diabetic retinopathy (Table 3).
Only two studies of participants were available for
inclusion in the subanalysis for white ancestry (Table 2).
No statistically signiﬁcant association of the VEGF
rs2010963 polymorphism with diabetic retinopathy was
found (OR 0.83 [95% CI 0.65–1.07], P  0.16) and insufﬁ-
cient studies were available for diabetic retinopathy sub-
type analyses.
Endothelial nitric oxide synthase. The endothelial ni-
tric oxide synthase (NOS3) gene is located on chromo-
some 7q35–36. Three NOS3 SNPs (rs1799983, rs41322052,
and rs3138808) met the inclusion criteria for meta-analy-
sis. The rs3138808 variant has been the most commonly
examined NOS3 diabetic retinopathy polymorphism, and
the 393 base pair insertion has been classiﬁed as the risk
variant. One study examining this polymorphism and
diabetic retinopathy in type 1 diabetes and seven studies in
type 2 diabetes were included in the analysis (Table 1).
There was no statistically signiﬁcant association between
rs3138808 and any form of diabetic retinopathy. Addition-
ally, no signiﬁcant association between any form of dia-
betic retinopathy and the rs1799983 (OR 1.11 [95% CI
0.94–1.31], P  0.23) or rs41322052 (1.06 [0.85–1.33], P 
0.60) were identiﬁed (Table 3).
Only two studies were available to be included in the
subanalysis for subjects of white ancestry (Table 2). No
statistically signiﬁcant association was found with the
NOS3 rs3138808 polymorphism and diabetic retinopathy
development (OR 0.71 [95% CI 0.28–1.75], P  0.45) and
insufﬁcient studies were available for diabetic retinopathy
subtype analysis.
DISCUSSION
Diabetic retinopathy remains one of the leading causes of
blindness in the developed world (1). There is strong
evidence for a genetic component in the development of
diabetic retinopathy, independent of other established risk
factors (13–17). Despite a large number of candidate gene
studies on diabetic retinopathy, the genetic evidence thus
far for an association with the development of or severity
of diabetic retinopathy has been conﬂicting. This is largely
accounted for by varying participant ethnicity, study de-
sign, differences in retinopathy grading scales, and in
particular suboptimal power.
The current meta-analysis comprehensively assesses the
risk of diabetic retinopathy in relation to every published
candidate gene meeting inclusion criteria. Eighty-two
studies examining 20 genes and 34 SNPs were analyzed.
Pathways involved in the pathogenesis of diabetic retinop-
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phisms in this meta-analysis are described in detail below.
Renin-angiotensin system. ACE is involved in the con-
version of angiotensin I to angiotensin II (ATII). ATII
mediates its hemodynamic effects through signaling via
angiotensin type 1 (AT1) and type 2 (AT2) receptors.
Vascular remodeling and proliferation occurs mainly via
the AT1 receptor (23). All components of the renin-
angiotensin system (RAS) have been shown to be ex-
pressed in the retina (24). The physiologic effects of ATII
in the eye include the regulation of intraocular blood ﬂow
and pressure, promotion of capillary growth, enhancing
vascular permeability, increasing oxidative stress, and the
regulation of cell growth via the expression of various
growth factors including VEGF, insulin-like growth factor,
and platelet-derived growth factor (23).
Clinical evidence also supports the role for the RAS
system in diabetic retinopathy pathogenesis. The EURO-
DIAB Controlled Trial of Lisinopril in Insulin-Dependent
Diabetes (EUCLID) trial provided evidence for lisinopril,
an ACE inhibitor, decreasing the progression of diabetic
retinopathy by 50% (25). In addition, animal studies have
shown that ACE inhibitors and AT1 receptor blockers can
prevent retinal neovascularization (26).
The ACE INS/DEL polymorphism in intron 16 had the
largest number of subjects to be genotyped for any poly-
morphism and the largest number of studies to include
participants of white ancestry. Three-quarters of the stud-
ies included participants of white ancestry. There was no
statistically signiﬁcant association of the INS/DEL poly-
morphism of the ACE gene with diabetic retinopathy or
diabetic retinopathy subtypes in type 1, type 2, or com-
bined diabetes. This is consistent with the ﬁndings of the
majority of the included studies examining this polymor-
phism in this meta-analysis. Two other meta-analyses have
examined the association of the INS/DEL of the ACE gene
with diabetic retinopathy development. Fujisawa et al.
(27) examined 12 studies, including type 1 and type 2
diabetic subjects. Wiwanitkit (28) examined four studies
and included type 2 diabetic subjects only. Both analyses
also found no statistically signiﬁcant association with this
polymorphism and the development of diabetic retinopathy.
Polyol pathway. Aldose reductase (ALR) is a rate-limiting
enzyme of the polyol pathway, which catalyzes NADPH-
dependent reduction of glucose to sorbitol. This pathway
leads to the intracellular accumulation of sorbitol and is
primarily active under hyperglycemic conditions (29). Sev-
eral mechanisms have been proposed to explain the
pathogenesis of diabetic microvascular complications, in-
cluding the induction of osmotic stress and the activation
of protein kinase C as well as pathogenic vascular and
hemodynamic alterations (8). ALR has been identiﬁed in
human pericytes, which exhibit an active polyol pathway
(30). Animal studies have shown that cultured mural cells
from the retinal capillaries of adult rhesus monkeys un-
dergo cellular degeneration after exposure to high glucose
levels, with ALR being isolated from these mural cells (31).
The sorbitol pathway is also biologically plausible as it is
involved in the selective degeneration of human mural
cells in NPDR (32). Induced hyperglycemia in dogs with
galactosemia has similarly shown retinal vascular changes
including microaneurysm formation, degeneration of reti-
nal pericytes, retinal hemorrhages, and nonperfused or
acellular vessels (33).
The AKR1B1 gene had the largest number of studies
examining the relationship of its polymorphisms to dia-
betic retinopathy development, regardless of ethnicity.
The z2 microsatellite showed the most signiﬁcant asso-
ciation with diabetic retinopathy, especially in type 2
diabetes, conferring risk also in PDR and NPDR subtypes.
The z2 and z microsatellite conferred protection against
overall diabetic retinopathy and NPDR, respectively, and
both were protective against PDR when compared with
NPDR in type 2 diabetes. The majority of studies included
in this meta-analysis have individually reported a risk for
diabetic retinopathy with the z2 microsatellite; however,
the z microsatellite was not found to be statistically
signiﬁcant by most studies, with only a ﬁfth of the studies
individually reporting z2 to be protective against diabetic
retinopathy. The vast majority of studies have included
participants of non-white ancestry; however, those of
white ancestry found the z2 microsatellite to confer risk
and z2 to confer protection against overall diabetic
retinopathy in combined diabetes.
The T allele of the AKR1B1 promoter SNP rs759853
conferred protection against diabetic retinopathy in type 1
diabetes of any ancestry and also of white ancestry alone.
This protection against diabetic retinopathy in type 1
diabetes has also been found in the individual studies
examining this polymorphism.
VEGF. VEGF is a multifunctional cytokine that promotes
angiogenesis and is a potent mediator of microvascular
permeability. Diabetic microvascular changes in the retina
lead to hypoxia, a stimulator of VEGF production (34).
VEGF has been found to have a signiﬁcant role in the
development of diabetic retinopathy by inducing hyperper-
meability of retinal vessels, breakdown of the blood–
retinal barrier, and neovascularization in PDR (35–37).
Complications such as retinal edema and blinding vitreous
hemorrhage arise as a result of the abnormal barrier
function of vessels and the growth of new vessels, which
are fragile and prone to rupture.
VEGF protein expression has been shown to be inﬂuenced
by genetic variation in the VEGF gene (38). VEGF levels in
the vitreous of patients with PDR are signiﬁcantly elevated
when compared with the vitreous of diabetic eyes without
PDR and control subjects without diabetes (39,40). VEGF
inhibition has been shown to result in a marked reduction in
retinal neovascularization (41) and prevention of the blood–
retinal barrier breakdown (42), further supporting its role in
diabetic retinopathy development.
The VEGF gene had the largest number of individual
SNPs examined in relation to diabetic retinopathy. Of
these six polymorphisms, the G variant of the rs2010963
polymorphism was found to signiﬁcantly protect against
the development of NPDR in type 2 diabetes but not with
overall diabetic retinopathy development. In keeping with
the ﬁndings of this meta-analysis, the majority of studies
reported no statistically signiﬁcant association of this
polymorphism with any diabetic retinopathy development
in type 2 diabetes, regardless of ethnicity.
NO pathway. Endothelial NO synthase (eNOS) is an
enzyme produced by endothelial cells. NO derived from
eNOS is a key endogenous vasodilator (43). It is also
believed to be important in the promotion of angiogenesis
and regulation of VEGF expression (44). A low concentra-
tion of eNOS is believed to be necessary to maintain
endothelial function (45) with experimental deﬁciency of
eNOS shown to signiﬁcantly decrease retinal neovascular-
ization in a mouse model (46). Aqueous NO levels have
also been found to play an important role in the progres-
sion of diabetic retinopathy, with levels signiﬁcantly
S. ABHARY AND ASSOCIATES
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found to be signiﬁcantly elevated in PDR vitreous when
compared with nondiabetic subjects (48), making the
eNOS gene (NOS3) a biologically plausible candidate for
susceptibility to diabetic retinopathy development.
The NOS3 rs3138808 polymorphism was the most stud-
ied polymorphism, and the majority of studies included
participants of nonwhite ancestry. No statistically signiﬁ-
cant association was found with diabetic retinopathy
development regardless of ethnicity and for whites alone,
consistent with the ﬁndings of the majority of the included
studies. All other NOS3 polymorphisms did not show
statistically signiﬁcant associations with the development
of diabetic retinopathy.
Data on the remaining 27 SNPs examined by a minimum
of two and maximum of ﬁve studies revealed the
rs2910964 SNP of the ITGA2 gene and rs13306430 of the
ICAM1 gene to be signiﬁcantly associated with diabetic
retinopathy. Both of these variants were examined in type
2 diabetes only and by the minimum allowable two studies
each. Unless further replicative studies are undertaken,
the importance of these genes in diabetic retinopathy may
remain unclear. Zintzaras et al. (49) performed a meta-
analysis of ﬁve studies examining the link between the
C677T polymorphism of the methylenetetrahydrofolate
reductase (MTHFR) gene and development of diabetic
retinopathy in type 2 diabetes. Unlike our results, a
borderline association between C677T transition and the
risk of development diabetic retinopathy (OR 1.39 [95% CI
1.05–1.83], P  0.08) was reported.
Because of the publication deadline for included stud-
ies, some polymorphisms, such as those recently reported
in the erythropoietin gene (50), were unable to be included
in the meta-analysis as further studies have not as yet been
reported. The deﬁnition of diabetic retinopathy requires
the minimum of microaneurysm presence in a diabetic
individual (34); however, several deﬁnitions and criteria
exist for the subclassiﬁcation of diabetic retinopathy and
preferences have been variable among included studies,
with many studies deﬁning diabetic retinopathy without
the use of standardized scales. Additionally, confounding
factors such as glycemic control have not been adjusted
for in calculation of the ORs of polymorphisms included in
this meta-analysis, as this information provided by in-
cluded studies have often been incomplete and nonstand-
ardized deﬁnitions were used. Therefore, these are
accepted as limitations of this meta-analysis, with some
being implicit in the meta-analysis concept when dealing
with a large number of studies with different design and
reporting style.
In conclusion, this meta-analysis has found that se-
quence variation within the AKR1B1 gene are the most
signiﬁcantly associated with diabetic retinopathy develop-
ment among those genes qualifying for inclusion. This
result supports more detailed research into the role of the
AKR1B1 gene in diabetic retinopathy to determine which
variants are causally associated and their mechanism of
action. Genetic research on diabetic retinopathy suscepti-
bility has the potential for a direct positive impact on
patient management by ultimately altering screening re-
gimes in an individualized manner for a disease that is of
major and increasing public health concern. Although
much work has focused on dissecting the genetics of
diabetes itself, considerably less has been conducted into
the molecular mechanisms leading to its speciﬁc compli-
cations, including diabetic retinopathy and its subtypes.
Although NPDR and PDR are commonly subanalyzed in
genetic studies, very few studies have reported on genetic
associations with the common subtype of macular edema,
that is a frequent cause of visual disability in diabetic
subjects. This is an area that requires further exploration.
Future genetic studies should also include genome-wide
association studies to identify diabetic retinopathy suscep-
tibility loci that have not been previously considered as
candidates to assist with a better understanding of the
pathogenesis of this debilitating sight-threatening diabetes
complication.
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